Australian High Court Rules Against Myriad's BRCA1 Patent Claims | GenomeWeb

NEW YORK (GenomeWeb) – The High Court of Australia has ruled that a nucleic acid isolated from the body encoding a BRCA1 protein and harboring variations that confer increased risk of breast and ovarian cancer is not a patentable invention as defined by the country's laws.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.